Detalles de la búsqueda
1.
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Hematol Oncol
; 42(1): e3249, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38287529
2.
Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis.
Ann Hematol
; 103(5): 1655-1664, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236391
3.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Blood
; 137(25): 3507-3517, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33651883
4.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36632738
5.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Hematol Oncol
; 39(3): 326-335, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739461
6.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33378569
7.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Am J Hematol
; 98(9): E237-E240, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382471
8.
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Am J Hematol
; 98(2): E24-E27, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36349541
9.
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
Haematologica
; 107(6): 1470-1473, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35199505
10.
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.
Ann Hematol
; 101(4): 929-931, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34302519
11.
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Am J Hematol
; 92(6): 529-535, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28295527
12.
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
Am J Hematol
; 97(3): E95-E99, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34904743
13.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Am J Hematol
; 97(5): E176-E180, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35170793
14.
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Hematol Oncol
; 39(4): 570-574, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34258787
15.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Am J Hematol
; 96(8): E269-E272, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878220
16.
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Am J Hematol
; 96(8): E306-E310, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33989438
17.
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Am J Hematol
; 96(5): E168-E171, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33580969
18.
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Br J Haematol
; 187(1): e8-e11, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31364153
19.
Prenatal diagnosis of proximal partial trisomy 1q confirmed by comparative genomic hybridization array: molecular cytogenetic analysis, fetal pathology and review of the literature.
Birth Defects Res A Clin Mol Teratol
; 100(4): 284-93, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24677675
20.
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.
EClinicalMedicine
; 72: 102592, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38633575